Podcast

Focusing on Adolescent and Young Adult Cancer

Author(s):

Kristie L. Kahl

In this week’s episode, we spoke with a young adult and a child life specialist who discussed the importance of focusing on the needs of AYAs with cancer.

The middle — an area many adolescent and young adults (AYAs) with cancer find themselves.

While their physical and emotional needs tend to be quite different, many institutions fail to focus on the specific needs of AYAs who don’t fall under either the pediatric or adult checklist.

In this week’s episode of CURE® Talks Cancer, we spoke with a young adult who was diagnosed with acute myeloid leukemia, as well as a child life specialist about a program at CHOC Children’s Hospital designed to address the specific needs of AYAs affected by cancer.

Related Videos
Image of Dr. Jorge Cortes; a man with short dark hair wearing a suit.
Image of a man with brown hair.
Image of a woman with short brown hair and glasses.
Image of a woman with short brown hair and glasses.
Image of a man with brown hair and a suit and tie.
Image of a woman with brown bobbed hair with glasses.
Related Content
Illustration of blood cells.
November 20th 2024

The FDA Approves Labeling Update for Sandoz in the Treatment of B-Cell CLL

Ryan Scott
The FDA has approved updated drug labeling for Sandoz in the treatment of B-cell chronic lymphocytic leukemia.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
"FDA" text.
November 15th 2024

FDA Approves Revuforj for Relapsed/Refractory Acute Leukemia Subset

Darlene Dobkowski, MA
Revuforj was approved by the FDA for adults and children with relapsed/refractory acute leukemia with a KMT2A translocation.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Image of an orange background with the words "FDA Approval, developing story."
November 8th 2024

FDA Approves CAR-T Cell Therapy for Relapsed or Refractory B-Cell ALL

Darlene Dobkowski, MA
The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based on findings from the FELIX trial.
"FDA" text.
November 1st 2024

Oncology Drugs Approved by the FDA in October 2024

Darlene Dobkowski, MA
During October, the FDA approved drugs to treat diseases including breast cancer, lung cancer, leukemia and gastric cancer.